Gastroenterology
Volume 138, Issue 2 , Pages 493-502 , February 2010

Des-γ-Carboxy Prothrombin and α-Fetoprotein as Biomarkers for the Early Detection of Hepatocellular Carcinoma

  • Anna S. Lok

      Affiliations

    • Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan
    • Corresponding Author InformationReprint requests Address requests for reprints to: Anna S. Lok, MD, Division of Gastroenterology, University of Michigan Health System, 3912 Taubman Center, SPC 5362, Ann Arbor, MI 48109. fax: 734-936-7024
    • ,
  • Richard K. Sterling

      Affiliations

    • Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, Virginia
    • ,
  • James E. Everhart

      Affiliations

    • Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland
    • ,
  • Elizabeth C. Wright

      Affiliations

    • Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland
    • ,
  • John C. Hoefs

      Affiliations

    • Division of Gastroenterology, University of California-Irvine, Irvine, California
    • ,
  • Adrian M. Di Bisceglie

      Affiliations

    • Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, St. Louis, Missouri
    • ,
  • Timothy R. Morgan

      Affiliations

    • Division of Gastroenterology, University of California-Irvine, Irvine, California
    • Gastroenterology Service, VA Long Beach Healthcare System, Long Beach, California
    • ,
  • Hae–Young Kim

      Affiliations

    • New England Research Institutes, Watertown, Massachusetts
    • ,
  • William M. Lee

      Affiliations

    • Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, Texas
    • ,
  • Herbert L. Bonkovsky

      Affiliations

    • Department of Medicine, University of Connecticut Health Center, Farmington, Connecticut
    • Department of Molecular and Structural Biology and The Liver-Biliary-Pancreatic Center, University of Connecticut Health Center, Farmington, Connecticut
    • ,
  • Jules L. Dienstag

      Affiliations

    • Gastrointestinal Unit (Medical Services), Massachusetts General Hospital and the Department of Medicine, Harvard Medical School, Boston, Massachusetts
    • ,
  • HALT-C Trial Group

Received 23 July 2009 ,Accepted 13 October 2009.

References 

  1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–2150
  2. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004;127:S27–S34
  3. Everhart JE. Primary liver cancer. In:  Everhart JE editors. Burden of digestive diseases in the United States (Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases). Washington, DC: US Government Printing Office; 2008;p. 49–52NIH Publication No. 09-6443 2008
  4. Stravitz RT, Heuman DM, Chand N, et al. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med. 2008;121:119–126
  5. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–1236
  6. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417–422
  7. McMahon BJ, Bulkow L, Harpster A, et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology. 2000;32:842–846
  8. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma (Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver). J Hepatol. 2001;35:421–430
  9. Makuuchi M, Kokudo N, Arii S, et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res. 2008;38:37–51
  10. Aoyagi Y, Oguro M, Yanagi M, et al. Clinical significance of simultaneous determinations of α-fetoprotein and des-γ-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma. Cancer. 1996;77:1781–1786
  11. Nomura F, Ishijima M, Kuwa K, et al. Serum des-γ-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma. Am J Gastroenterol. 1999;94:650–654
  12. Mita Y, Aoyagi Y, Yanagi M, et al. The usefulness of determining des-γ-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer. 1998;82:1643–1648
  13. Ishii M, Gama H, Chida N, et al. Simultaneous measurements of serum α-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma (South Tohoku District Study Group). Am J Gastroenterol. 2000;95:1036–1040
  14. Hamamura K, Shiratori Y, Shiina S, et al. Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-γ-carboxy prothrombin and low serum α-fetoprotein. Cancer. 2000;88:1557–1564
  15. Nakamura S, Nouso K, Sakaguchi K, et al. Sensitivity and specificity of des-γ-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol. 2006;101:2038–2043
  16. Okuda H, Obata H, Nakanishi T, et al. Production of abnormal prothrombin (des-γ-carboxy prothrombin) by hepatocellular carcinoma (A clinical and experimental study). J Hepatol. 1987;4:357–363
  17. Liebman HA, Furie BC, Tong MJ, et al. Des-γ-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med. 1984;310:1427–1431
  18. Stenflo J, Fernlund P, Egan W, et al. Vitamin K dependent modifications of glutamic acid residues in prothrombin. Proc Natl Acad Sci U S A. 1974;71:2730–2733
  19. Marrero JA. Screening tests for hepatocellular carcinoma. Clin Liver Dis. 2005;9:235–251
  20. Ikoma J, Kaito M, Ishihara T, et al. Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-γ-carboxy prothrombin: a prospective study. Hepatogastroenterology. 2002;49:235–238
  21. Pateron D, Ganne N, Trinchet JC, et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol. 1994;20:65–71
  22. Oka H, Tamori A, Kuroki T, et al. Prospective study of α-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology. 1994;19:61–66
  23. Bolondi L, Sofia S, Siringo S, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost-effectiveness analysis. Gut. 2001;48:251–259
  24. Tong MJ, Blatt LM, Kao VW. Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America. J Gastroenterol Hepatol. 2001;16:553–559
  25. Chalasani N, Horlander JC, Said A, et al. Screening for hepatocellular carcinoma in patients with advanced cirrhosis. Am J Gastroenterol. 1999;94:2988–2993
  26. Izuno K, Fujiyama S, Yamasaki K, et al. Early detection of hepatocellular carcinoma associated with cirrhosis by combined assay of des-γ-carboxy prothrombin and α-fetoprotein: a prospective study. Hepatogastroenterology. 1995;42:387–393
  27. Lee WM, Dienstag JL, Lindsay KL, et al. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials. 2004;25:472–492
  28. Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med. 2008;359:2429–2441
  29. Di Bisceglie AM, Sterling RK, Chung RT, et al. Serum α-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol. 2005;43:434–441
  30. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–699
  31. Lok AS, Seeff LB, Morgan TR, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009;136:138–148
  32. Gupta S, Bent S, Kohlwes J. Test characteristics of α-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C (A systematic review and critical analysis). Ann Intern Med. 2003;139:46–50
  33. Marrero JA, Su GL, Wei W, et al. Des-γ carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology. 2003;37:1114–1121
  34. Lamerz R, Runge M, Stieber P, et al. Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseases. Anticancer Res. 1999;19:2489–2493
  35. Toyoda H, Kumada T, Osaki Y, et al. Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clin Gastroenterol Hepatol. 2006;4:1528–1536
  36. Volk ML, Hernandez JC, Su GL, et al. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark. 2007;3:79–87
  37. Yano Y, Yamashita F, Kuwaki K, et al. Clinical features of hepatitis C virus-related hepatocellular carcinoma and their association with α-fetoprotein and protein induced by vitamin K absence or antagonist-II. Liver Int. 2006;26:789–795
  38. Nguyen MH, Garcia RT, Simpson PW, et al. Racial differences in effectiveness of α-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. Hepatology. 2002;36:410–417
  39. Beale G, Chattopadhyay D, Gray J, et al. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer. 2008;8:200

 Conflicts of interest The authors disclose the following:Financial relationships of the authors with Hoffmann-La Roche, Inc., are as follows: A.S. Lok is a consultant; R.K. Sterling is a consultant, receives research support, and is on the speaker's bureau; J.C. Hoefs is on the speaker's bureau; T.R. Morgan is a consultant, on the speaker's bureau, and receives research support; A.M. Di Bisceglie is a consultant, on the speaker's bureau, and receives research support; W.M. Lee receives research support; and H.L. Bonkovsky receives research support. Financial relationships of the authors with Eisai Co, Ltd, are as follows: A.S. Lok receives research support. The remaining authors disclose no conflicts.

 Funding Supported by the National Institute of Diabetes & Digestive & Kidney Diseases (contract numbers are listed below); the National Institute of Allergy and Infectious Diseases (NIAID); the National Cancer Institute; the National Center for Minority Health and Health Disparities; by General Clinical Research Center and Clinical and Translational Science Center grants from the National Center for Research Resources and National Institutes of Health (grant numbers are listed below); by Eisai Co, Ltd, through a Materials Cooperative Research and Development Agreement (M-CRADA) with the National Institutes of Health for testing of des-γ-carboxy prothrombin; and by Hoffmann–La Roche, Inc, through a Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health.

 View this article's video abstract at www.gastrojournal.org

PII: S0016-5085(09)01857-5

doi: 10.1053/j.gastro.2009.10.031

Gastroenterology
Volume 138, Issue 2 , Pages 493-502 , February 2010

Article Tools

* Image Usage & Resolution